# A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

> **NCT03015623** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sentien Biotechnologies, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **BIOLOGICAL:** SBI-101
- **DEVICE:** Sham

## Key facts

- **NCT ID:** NCT03015623
- **Lead sponsor:** Sentien Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-20
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015623, "A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT03015623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*